Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
14-11-2019
Allergan to buy Australian tissue repair company for $95m
12-02-2018
Sanofi to acquire Ablynx for €3.9bn
29-01-2018
Choreograph / iStockphoto.com
Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Biopharmaceutical merger, biotech acquisition, cancer research, tucatinib, oncology development
